We sought to investigate non-coronary vascular calcification and its influence on changes in vascular inflammation.
Introduction
study, a phase 2 randomized clinical trial that investigated the effects of the cholesteryl ester transfer protein inhibitor, dalcetrapib, on the vasculature.
Specifically, we hypothesised (1) that the presence of classical cardiovascular risk factors would increase both baseline calcification and its progression in the ascending aorta, aortic arch, and carotid and coronary arteries over 6 months. We also hypothesized (2) that arteries with the highest baseline calcium levels would undergo the greatest additional calcification over the next 6 months. 8 
Methods
The current study is a post hoc analysis of the dal-PLAQUE study. The study design, methods and primary results have already been published (8, 9) . dal-PLAQUE was a phase 2b, double-blind, randomized, placebo-controlled study that investigated the effect of dalcetrapib on vessel wall inflammation assessed by 18 F-fluorodeoxyglucose (FDG) PET/CT. Inclusion criteria were males and females aged 18 to 75 years, with previous known CHD or at high risk thereof (diabetes or a 10-year risk of CHD events >20% by Framingham Risk scoring), triglyceride concentrations ≤400 mg/dl, LDL cholesterol (LDL-C) concentrations <100 mg/dl or on maximum tolerated doses of statins, and a target to background ratio (TBR) of 1.6 or higher in an index vessel (either right carotid, left carotid, or ascending aorta), as identified by 18 F-FDG uptake measured by PET/CT during the screening period.
PET/CT imaging
Details of FDG PET/CT imaging procedures, quantification of tracer uptake, and analyses have been published previously (8) . FDG-PET/CT imaging of the carotid arteries and ascending aorta was performed at baseline as well as after 3 and 6 months of follow-up.
Arterial FDG uptake was quantified by manually delineating a region of interest (ROI) on co-registered transaxial PET/CT images. A circular ROI was drawn to encompass the vessel wall on each contiguous axial segment. Next, the maximum arterial standardized uptake value (SUV) was determined, being defined as the decaycorrected tissue concentration of FDG in kBq/ml, adjusted for the injected FDG dose and the body weight of the patient. We calculated TBR from the ratio of SUV of the artery compared with background venous activity and recorded values for the individual vessels (aorta and mean right and left carotid artery) using previously reported methods (8) . The vessel with the highest maximum TBR at baseline was considered the index vessel. Mean of maximum (MeanMax) TBR was the average of the maximal TBR values from each artery. The most diseased segment (MDS) was defined as the average maximum TBR of a group of 3 contiguous slices, centered on the slice with the highest maximum TBR, the single hottest slice (SHS). Active slices were defined as those with TBR >1.6. For the current analyses, we used baseline values and change in the above indices at 6 months for both the index vessel and an average of both carotid arteries.
Assessment of vascular calcification
Analysis was performed on baseline and 6-month CT scans by an experienced observer (Francis R Joshi) blinded to both clinical details and scan order.
Unenhanced CT imaging acquired for localization of FDG PET uptake was loaded into the open-source DICOM viewer OsiriX (version 4.0, 64-bit, OsiriX Imaging Software, Geneva, Switzerland) and re-sampled to a 3 mm transaxial thickness.
Using the freely available 'Calcium Scoring' plug-in, vascular calcification (based on an attenuation threshold of 130 Hounsfield Units in 3 contiguous voxels, after the method of Agatston (10)) was analyzed on consecutive transaxial slices along the length of the arterial segment. The extent of calcification was expressed both as a score in Agatston units and as a volume in cubic millimeters. The measurement of thoracic aortic and coronary artery calcification from ungated CT studies is accurate and highly concordant with values derived from gated studies (11) . Paired (baseline and follow-up) studies were visually compared to ensure that the same length of artery was analyzed on both scans.
Coronary artery calcification was scored as the sum of all 3 epicardial vessels.
Ascending aortic calcification was scored on transaxial slices from the main pulmonary artery inferiorly to 1 slice below the aortic arch. Aortic arch calcification was scored on transaxial slices from the most inferior slice at which the ascending and descending aorta were contiguous to the origin of the great vessels. Calcification was scored if it appeared to be in the vascular wall. When isolated calcification of the ligamentum arteriosum was obvious it was not scored. Carotid arterial calcification was assessed bilaterally from the most inferior slice visible on the CT scan to the base of the skull, and then summed.
Coronary calcium was not recorded in those who had undergone prior percutaneous coronary intervention or coronary artery bypass surgery. If the participant had evidence of prior coronary bypass surgery, the ascending aorta was not analysed, due to artefacts from the surgical clips used in fashioning the grafts. If possible, calcification in the aortic arch was still scored in such cases, provided there were no significant artefacts from sternal wires or surgical clips. Noisy CT images of the neck, with artefacts from dental prostheses, were excluded from analyses of the carotid arteries.
Statistical analysis
Descriptive data are presented as median (Q1, Q3) as well as frequencies with proportions for nominal variables as appropriate.
The following measures of progression of vascular calcification were used:
1. The absolute difference between baseline and follow-up 2. The difference between the square root of baseline and square root of followup score (the 'SQRT method' of Budoff et al (12)). A cut-off of 2.5 was used to identify a change in calcification from baseline beyond the known interscan variability of coronary calcium scores, as per Hokanson et al. (13) .
Baseline calcium scores in the presence or absence of risk factors were compared after square root transformation using analysis of variance (ANOVA). Baseline calcium scores were dichotomized into 'zero' and 'non-zero', and the effect of a nonzero score on progression of calcification (absolute change after square root transformation) was analyzed using ANOVA. The effect of a 'non-zero' score on absolute changes in PET indices at 3 and 6 months were assessed through linear mixed models with a visit by score interaction. The effect of dalcetrapib treatment on calcium progression (absolute change on original scale and also after square root transformation) was analyzed using ANOVA with baseline and treatment in the model. Two-sided p-values are reported throughout, with no adjustment for multiple testing. The lack of adjustment for multiple testing was pre-planned and stated in our statistical analysis plan for all Dalplaque manuscripts (8), (9) . Here, we provide raw p values that should be interpreted in the light of multiple testing.
Results dal-PLAQUE recruited 130 patients with a median age of 65 years, most (82%) of whom were male. Baseline demographics are reported in Table 1 . After exclusions, both baseline and 6-month CT images yielded data for the aortic arch in 98 patients (75%), the ascending aorta in 80 patients (62%), the carotid arteries in 102 patients (78%), and the coronary arteries in 32 patients (25%). Data were only included when the whole arterial territory was visualized on both PET/CT scans.
At baseline, the median (Q1, Q3) calcium score in the aortic arch was 161 (0, 852), in the combined carotid arteries 52 (0, 267) and 13 (0, 83) in the coronary arteries.
The median (Q1, Q3) calcium score in the ascending aorta was 0 (0, 0). Given the large number of zero scores (71 of 80 participants), it was not possible to analyze associations between cardiovascular risk factors and the baseline scores in the ascending aorta. Across all other arterial territories, baseline calcium scores were higher in those over the age of 65 as compared to younger participants (Table 2) .
Scores in the aortic arch were significantly higher in those having ever smoked (329 that the final stages of calcification are associated with a reduction in inflammatory activity (37). The point at which inflammation becomes less prominent is, however, still to be defined. 18 F-sodium fluoride holds promise as a means of imaging active calcification in vivo (38) and further longitudinal study of changes in the activity of both inflammation and calcification is needed to better understand these processes.
Limitations
This was a post-hoc analysis of data from the dal-PLAQUE study, with only 6 months between PET/CT imaging sessions. Consequently, despite the inclusion of a highrisk population, there was relatively little progression of vascular calcification during this short wondow. A significant number of scans were excluded from analysis of the coronary arteries because of prior coronary bypass surgery or coronary intervention.
Whilst coronary calcium scores on electrocardiogram-gated and ungated CT scans are highly correlated, the interscan variability on ungated scans is not known.
Comparison of ungated scans may therefore miss small increments in coronary calcium scores, but is likely to be less of a problem in the other vascular beds studied. Finally, as in any post-hoc data analysis, false positive findings are possible.
We advise caution in interpretation of our results, which need to be replicated in longer, larger, prospective studies.
Conclusions
Inflammation and calcification are important in both the progression of atherosclerosis and its clinical complications.
In this study, we have described the relationship between cardiovascular risk factors and both baseline and interval calcification in several arterial beds, as well as the interactions with inflammation in those territories. We have also provided data concerning the drivers of calcification progression and the lack of a significant effect of an HDL-raising therapy on calcification. Finally, we have provided the first report of aortic calcification progression outside of the context of subjects with renal failure.
These findings are important for providing a better understanding of the links between these pathological processes, and could help to improve both patient risk- 
